Home > Boards > US Listed > Medical - Drugs >

Seelos Therapeutics Inc (SEEL)

SEEL RSS Feed
Add SEEL Price Alert      Hide Sticky   Hide Intro
Moderator: beambe
Search This Board: 
Last Post: 4/22/2019 3:31:41 PM - Followers: 240 - Board type: Free - Posts Today: 0

Apricus Biosciences, Inc. (APRI) 

 

 

http://www.apricusbio.com/

 

 

 

 

Company Address:

11975 El Camino Real, Suite 300
San Diego, CA 92130
T (858) 222-8041

 CIK:   0001017491

Apricus Website:    http://www.apricusbio.com/index.html

 

 
 

NexACT® - Multi-Route Drug Delivery Technology

NexACT® Multi-Route drug delivery technology facilitates compounds crossing the lipid bilayer and yet biodegrades in vivo to natural amino acids and natural fatty acids.

This technology is useful for:
  • Penetrating, proprietary, topical & transdermal formulations.
    Improving oral bioavailability of poorly soluble, poorly permeating compounds (BCS class 2-4)
    Delivering siRNA therapeutics into the cells; in vivo validated
    Development of more effective, penetrating cosmeceutic formulations
    Preservative

The safety and permeation properties of this proprietary drug delivery technology was demonstrated in the Vitaros® product which was approved for the treatment of erectile dysfunction in November 2010 by Health Canada, and approved by the European Union in June 2013.  Vitaros has been launched in all European Union countries by partner pharmaceutical companies.  Additional agreements for marketing Vitaros have been established.  For more information see the company's most recent 10K SEC filing.

In September 2015 the company anounced an agreement with Allergan to reacquire marketing rights for Vitaros in the U.S.  The company expects to resubmit a filing for FDA approval of Vitaros in the second half of 2016.  For more information see the company's most recent 10K SEC filing.


The company expects to initiate a Phase IIb clinical trial for RayVa to treat Reynaud's Syndrome in the second half of 2016.

In October 2014, the company acquired U.S. development and licensing rights to Fispemifene, a Selective Estrogen-Receptor Modulator (SERM) for treatment of secondary hypogonadism.  In March 2016 the company discontinued development Fispemifene after disappointing Phase IIb results.
.

 Filings:  http://www.sec.gov/cgi-bin/browse-edgar?company=&match=&CIK=0001017491&filenum=&State=&Country=&SIC=&owner=exclude&Find=Find+Companies&action=getcompany

Share Structure:
Outstanding Shares
 61,78M

Authorized Shares
75,000,000
  

Investor Relations:
ir@apricusbio.com
Tel: +1-858 222-8041

Matthew Beck
The Trout Group
:(646)378 2933

 

 

 

All messages, including iBox content, are the opinion of the posters, are no substitute for your own research, and should not be relied upon for stock trading or any other purpose.

 

Please keep your posts on topic because your message(s) will probably be deleted when:
* Posting content that's off-topic to the subject of this board;
* Posting statements that don't add value to the discussion; or
* When you violate any other posting term of the iHub User Agreement: http://investorshub.advfn.com/boards/complex_terms.asp

 


                                                                           
Image result for vitaros                                                  

Image result for vitaros

SEEL
Current Price
Volume:
Bid Ask Day's Range
  • 1D
  • 1M
  • 2M
  • 3M
  • 6M
  • 1Y
  • 2Y
  • 3Y
  • 5Y
SEEL News: Seelos Therapeutics to Participate at the Jefferies 2019 Global Healthcare Conference in NYC 04/16/2019 08:00:00 AM
SEEL News: Statement of Ownership (sc 13g) 04/15/2019 05:28:10 PM
SEEL News: Proxy Statement (definitive) (def 14a) 04/12/2019 05:17:53 PM
SEEL News: Current Report Filing (8-k) 04/08/2019 04:17:08 PM
SEEL News: Seelos Therapeutics Provides Update on Pipeline Developments and Corporate Highlights 03/28/2019 05:00:00 PM
PlusOneCoin Top Posts
No plusone'd posts yet. Be the first!
PostSubject
#29601   Wait til Friday when it's at 2.25. Again. Boneride 04/22/19 03:31:40 PM
#29600   Hello team! I’m close to jumping back in RealLovePipes 04/22/19 02:18:31 PM
#29599   I'm staying with it, T-Down. Just gets to Boneride 04/19/19 02:32:31 PM
#29598   Short it, please! Moeclay 04/18/19 09:39:39 PM
#29597   Early stage? They have 2 trials approaching PH3 THey trickledownfacists 04/18/19 07:07:52 PM
#29596   They have $18M in the bank Their sanfilippo trial trickledownfacists 04/18/19 07:06:17 PM
#29595   All early stage biotechs have a continuous slow Leonard McKinley 04/18/19 06:44:51 PM
#29594   can anyone explain this slow, steady dive into Boneride 04/18/19 02:28:22 PM
#29593   Yes sir...that patent ?.. rabbit67 04/17/19 10:22:54 PM
#29592   It's not. Closer to 30% trickledownfacists 04/17/19 06:26:58 PM
#29591   Marketwatch has 148.42% of the float shorted. How Boneride 04/17/19 10:48:24 AM
#29590   3.04 six weeks ago and 3.04 today. This Boneride 04/17/19 10:22:39 AM
#29589   Go time. 24jg 04/16/19 10:46:16 PM
#29588   Patience is correct. If Ligand bought in February Moeclay 04/16/19 09:35:57 PM
#29587   Ligand pharmaceuticals...our partner holding 10 percent will surely rabbit67 04/16/19 05:54:43 PM
#29586   https://ca.proactiveinvestors.com/companies/news/218716/seelos-therapeutics-bloc booktrader 04/16/19 04:32:02 PM
#29585   That company's who's taken a 10 percent piece rabbit67 04/16/19 02:50:56 PM
#29584   Right?! Hopefully mergers on the way. curryhurry 04/16/19 11:13:59 AM
#29583   It would be nice if we merged Moeclay 04/16/19 09:35:03 AM
#29582   It usually happens in three's...(LOL) Moeclay 04/16/19 08:44:53 AM
#29581   Needed it. Down 7 of the last 10 Boneride 04/15/19 10:44:23 PM
#29580   There's your news enjoy....10 percent partner looks like rabbit67 04/15/19 09:40:44 PM
#29579   Ha....take that..shorties rabbit67 04/15/19 09:39:11 PM
#29578   After hours filing of 10% partner trickledownfacists 04/15/19 07:11:40 PM
#29577   It'll hover around 3.20 until there's news. Can't Boneride 04/12/19 11:37:04 PM
#29576   If there is great trial news it'll rip. The trickledownfacists 04/12/19 10:56:31 PM
#29575   She’s gonna run next week. 24jg 04/12/19 10:06:42 PM
#29574   Most Seeking Alpha articles are crap. Don't forget Boneride 04/12/19 01:39:13 PM
#29573   I agree. But going forward this company looks great. trickledownfacists 04/12/19 01:35:43 PM
#29572   Figured that, even more so now that BMY Moeclay 04/12/19 01:20:46 PM
#29571   Bs CaptStockWolf 04/12/19 01:11:02 PM
#29570   Was the Seeking Alpha article BS, or was Moeclay 04/12/19 10:19:44 AM
#29569   PH 3 ketamine trail starting this year. 6 pipeline trickledownfacists 04/12/19 10:15:45 AM
#29568   Pathetic. Like watching paint dry. Boneride 04/11/19 09:56:46 AM
#29567   Marketwatch has the short interest and I noticed Boneride 04/10/19 11:37:44 PM
#29566   yes. All of which warrants are possible Leonard McKinley 04/10/19 06:33:36 PM
#29565   I don't know the current short interest, but Moeclay 04/10/19 06:18:41 PM
#29564   With warrants that haven't been exercised yet.... trickledownfacists 04/10/19 05:58:08 PM
#29563   Wrong again. There are 22 million equivalent Leonard McKinley 04/10/19 05:38:23 PM
#29562   Ihub, yahoo, google finance, and vanguard all say trickledownfacists 04/10/19 04:17:30 PM
#29561   I hope you're right but that's not what Boneride 04/10/19 04:13:00 PM
#29560   No. 18 million float with 4 million shorted trickledownfacists 04/10/19 04:08:43 PM
#29559   1.34M shorted as of 3-29. 46.13% of the Boneride 04/10/19 04:06:06 PM
#29558   Where do you see that? I see 22% trickledownfacists 04/10/19 03:54:05 PM
#29557   Can someone explain why 46% of the float Boneride 04/10/19 03:52:57 PM
#29556   https://twitter.com/seelostx/status/1115691587940618240 They're hiring. booktrader 04/09/19 04:52:45 PM
#29555   Nice recovery trickledownfacists 04/09/19 02:05:39 PM
#29554   15% board ownership Float of 18M 20% short: squeeeeeeze Market cap trickledownfacists 04/09/19 11:36:20 AM
#29553   See, Trickledown ? What do I know ? Boneride 04/08/19 11:14:58 PM
#29552   Bristol-Myers Squibb came out of nowhere? Moeclay 04/08/19 10:12:39 PM
PostSubject